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excess of public enthusiasm for 
the project just became a fatal 
stampede. The fact of the matter 
is that the shares in Decode that 
were traded on the unregulated 
Icelandic market at that time went 
to unrealistic heights of over $60, 
and then collapsed dramatically 
to the area of well below $6. 
Even though Decode has 
reported some scientific progress 
since that time, including the 
discovery of gene variants 
responsible for some cases of 
prostate cancer, schizophrenia, 
and cardiovascular disease, the 
company’s financial fortunes 
never fully recovered from this 
crash. At the time of writing, 
NasDaq listed Decode shares 
trade at $4.97, nearly 50 per cent 
down from the price one year 
earlier. 
With the economic downturn 
and the newspaper reports about 
small investors ruined by it came 
a growing concern about the 
privacy issues. More and more 
Icelanders made use of their 
right to opt out of the medical 
database. Court cases were 
fought, and press reports have 
now pronounced the national 
medical database as dead. 
Decode’s press department has 
pumped out more than 40 press 
releases so far this year, not one 
of which has a topic related to the 
medical database that everybody 
talked about earlier.
Instead, Decode has turned 
into a more traditional biotech 
company and focused on drug 
discovery based on a few links 
between gene variants and 
common diseases that it has 
discovered so far. Products in 
its development pipeline include 
a drug for patients with specific 
genetic risk factors for heart 
attacks (phase III) and one for 
the treatment of peripheral artery 
disease (phase II). The change 
of direction is underlined by 
a few top-level appointments 
the company made this year, 
including that of Peter Goodfellow 
(formerly GlaxoSmithKline) to its 
board of directors. Genomics is 
likely to take a new turn here now.
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web page at www.michaelgross.co.ukA UK project to study genetics 
alongside health and lifestyle 
data, piloted in Manchester, has 
proved a success in no small part 
to the specific consent sought 
from participants by researchers. 
This pilot has now turned into 
the largest study of the genetic 
and environmental causes of 
disease rolled out across the UK. 
The UK Biobank aims to obtain 
DNA samples from up to 500,000 
people aged 40–69 and track their 
health. It is hoped the database 
will be used to find cures for killer 
illnesses such as heart disease, 
diabetes and cancer. The project 
received unanimous support from 
Britain has won both academic 
and public support for a major 
human genomics and health 
project. Nigel Williams reports.
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and its backers this summer 
following the Manchester pilot.
Letters will be sent to men 
and women in the target group 
by the end of the year, inviting 
them to attend one of a network 
of assessment centres to be 
set up in locations around the 
UK. Over the next three to four 
years, there will be around 35 
centres in the UK, each open for 
about six months. The centres 
will be located in areas where 
there are about 150,000 men and 
women aged 40–69 living within a 
15  kilometre radius.
The project will gather, store 
and protect a vast bank of 
medical data and material. 
The aim is to give accredited 
researchers a rich resource which 
they can use to examine how 
the complex interplay of genes, 
lifestyle and environment affects 
our risk of disease.
The £61 million project is being 
funded by the Medical Research Agreed: Support from people in Manchester in the pilot study has boosted the plan 
to go national for a long-term genomics database. (Photo: Marketing Manchester/
David Oates.)
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While many British appear happy 
for researchers to look at their 
genetic profile in terms of health, 
a recent television programme 
(100% English, Channel Four) 
debunked any notion that a 
person’s sense of Englishness has 
a genetic basis.
The programme took a handful 
of proudly English individuals 
each convinced of their purely 
Anglo- Saxon heritage, then 
confronted them with DNA 
evidence taken from mouth swabs 
to the contrary. It then recorded 
their responses to the results. 
Carol Thatcher, daughter of the 
former prime minister, Margaret 
Thatcher, learned that her DNA 
results suggested that she was 24 
per cent Middle Eastern in origin. 
She looked disconcerted. “Do you 
mean Mediterranean?” she asked, 
hopefully. No, said the presenter, 
historian Andrew Graham-Dixon. 
He meant Saudi Arabia, Iraq, 
Libya, places like that. Most of 
the participants tied themselves 
in knots over the question of 
Englishness, as their idea of what 
was proper struggled to hold sway 
over deeper feelings and a wish 
that their beliefs had a strong 
founding in their genetic ancestry.
The comedian Danny Blue, 
who revelled in his Englishness, 
asserted that the research 
would reveal no dilution in his 
Anglo- Saxon inheritance over 
the past dozen or so generations 
and was adamant that anybody 
claiming to be English should 
have a similar genetic history. 
Danny’s DNA turned out to 
reveal its origins as 10 per 
cent Middle Eastern, 11 per 
cent south Asian, 37 per cent 
south- eastern European and 43 
per cent northern European. “Bit 
of a mongrel, aren’t I”, he said 
reluctantly. He resolved that if you 
could trace back your ancestry 
two or three generations in this 
country, you could call yourself 
English.
With growing globalisation, the 
programme was a timely reminder 
of the differences between culture 
and ancestry.
Mediawatch: Genes are shown to 
provide no support for peoples’ 
belief in the cause of their 
‘Englishness’. Nigel Williams 
reports.
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Fluttering: It’s just flags not genes. (Picture: Charles Bowman/Photolibrary.)Council, the Wellcome Trust, 
the Department of Health, the 
Scottish Executive and the North 
West Regional Development 
Agency. A final protocol has 
been closely assessed by an 
independent international review 
panel set up by the funders.
In its report the panel 
concluded that “UK Biobank has 
the potential, in ways that are not 
currently available elsewhere, to 
support a wide range of research”. 
It also praised the planning of the 
project, and the way it had dealt 
with potential ethical problems.
The key role of participant 
consent has been highlighted 
by concerns raised last month 
that patient records in the UK’s 
National Health Service are 
planned to be loaded onto a 
national database. A survey 
amongst doctors and other health 
professionals found many uneasy 
about the storage of data without 
patients’ consent.
The development of the 
Biobank is therefore likely to 
highlight the issue of consent, 
flagged up in the international 
review, as a key basis of its 
operation. Rory Collins, UK 
Biobank’s principal investigator, 
was delighted that the project had 
been given the thumbs up this 
summer. He said: “For decades to 
come, the UK Biobank resource 
should provide researchers 
around the world with vital 
insights into some of the most 
distressing diseases of middle 
and old age”.
Colin Blakemore, MRC chief 
executive, said that the Biobank 
“offers enormous potential to find 
out more about the complex links 
between our genes, the lives we 
lead and our health.”
Health minister Andy Burnham 
said the endorsement of 
Biobank showed the UK was at 
the forefront of applying new 
genetics-based knowledge for the 
benefit of patients. 
But there remain some worries. 
Helen Wallace, of the group 
GeneWatch, said there was 
concern that research funding 
might be better used elsewhere. 
She said: “We would still like to 
see a much more open process 
of decision-making which actively 
involves members of the public.”
